Mizuho Increases Charles River Laboratories International (NYSE:CRL) Price Target to $230.00

Charles River Laboratories International (NYSE:CRL) had its price objective lifted by research analysts at Mizuho from $192.00 to $230.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Mizuho’s target price suggests a potential downside of 1.62% from the company’s current price.

CRL has been the subject of a number of other reports. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Royal Bank Of Canada began coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Morgan Stanley lifted their target price on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday. Finally, Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $220.75.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $233.79 on Monday. The stock’s 50-day simple moving average is $187.76 and its 200-day simple moving average is $185.75. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. Charles River Laboratories International has a 52 week low of $144.26 and a 52 week high of $237.86. The company has a market capitalization of $11.26 billion, a price-to-earnings ratio of -62.18, a PEG ratio of 2.66 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the previous year, the company earned $2.34 EPS. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, analysts expect that Charles River Laboratories International will post 11.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CRL. Tema Etfs LLC acquired a new position in Charles River Laboratories International during the fourth quarter worth approximately $26,000. Los Angeles Capital Management LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at about $42,000. Sfam LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $43,000. Activest Wealth Management grew its stake in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. increased its holdings in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.